Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1998 Jul;94(3):376–379. doi: 10.1046/j.1365-2567.1998.00524.x

The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production.

A C Peeters 1, M G Netea 1, B J Kullberg 1, T Thien 1, J W van der Meer 1
PMCID: PMC1364256  PMID: 9767420

Abstract

The balance between pro- and anti-inflammatory cytokines has been implicated in the pathogenesis of infectious and auto-immune diseases, and its modulation has been proposed as a potential therapeutic target. The results reported in the present study show that modulators of the renin-angiotensin system, such as the angiotensin-converting enzyme (ACE)-inhibitor captopril and the angiotensin II receptor type I antagonist valsartan, have potent inhibitory effects on the lipopolysaccharide (LPS)-stimulated production of pro-inflammatory cytokines tumour necrosis factor (TNF) and interleukin-1 (IL-1) in vitro. The anti-inflammatory cytokine IL-1Ra is increased by captopril, whereas IL-6 production is decreased by valsartan. These effects are exerted mainly at high concentrations of the drugs. Administration of one dose of captopril or valsartan in therapeutic dosages to patients with essential hypertension did not influence LPS-stimulated production of cytokines by whole blood. In conclusion, despite inhibitory effects on pro-inflammatory cytokine production in vitro, it is unlikely that captopril or valsartan could be used in anticytokine therapeutic strategies in vivo.

Full text

PDF
376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bleeker M. W., Netea M. G., Kullberg B. J., Van der Ven-Jongekrijg J., Van der Meer J. W. The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. Immunology. 1997 Aug;91(4):548–552. doi: 10.1046/j.1365-2567.1997.00285.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Casini-Raggi V., Kam L., Chong Y. J., Fiocchi C., Pizarro T. T., Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol. 1995 Mar 1;154(5):2434–2440. [PubMed] [Google Scholar]
  3. Chomarat P., Vannier E., Dechanet J., Rissoan M. C., Banchereau J., Dinarello C. A., Miossec P. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol. 1995 Feb 1;154(3):1432–1439. [PubMed] [Google Scholar]
  4. Dalekos G. N., Elisaf M. S., Papagalanis N., Tzallas C., Siamopoulos K. C. Elevated interleukin-1 beta in the circulation of patients with essential hypertension before any drug therapy: a pilot study. Eur J Clin Invest. 1996 Oct;26(10):936–939. doi: 10.1111/j.1365-2362.1996.tb02141.x. [DOI] [PubMed] [Google Scholar]
  5. Dalekos G. N., Elisaf M., Bairaktari E., Tsolas O., Siamopoulos K. C. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med. 1997 Mar;129(3):300–308. doi: 10.1016/s0022-2143(97)90178-5. [DOI] [PubMed] [Google Scholar]
  6. Delfraissy J. F., Galanaud P., Balavoine J. F., Wallon C., Dormont J. Captopril and immune regulation. Kidney Int. 1984 Jun;25(6):925–929. doi: 10.1038/ki.1984.111. [DOI] [PubMed] [Google Scholar]
  7. Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87(6):2095–2147. [PubMed] [Google Scholar]
  8. Drenth J. P., Van Uum S. H., Van Deuren M., Pesman G. J., Van der Ven-Jongekrijg J., Van der Meer J. W. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol (1985) 1995 Nov;79(5):1497–1503. doi: 10.1152/jappl.1995.79.5.1497. [DOI] [PubMed] [Google Scholar]
  9. Endres S., Ghorbani R., Lonnemann G., van der Meer J. W., Dinarello C. A. Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol. 1988 Dec;49(3):424–438. doi: 10.1016/0090-1229(88)90130-4. [DOI] [PubMed] [Google Scholar]
  10. Endres S., Whitaker R. E., Ghorbani R., Meydani S. N., Dinarello C. A. Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo. Immunology. 1996 Feb;87(2):264–270. doi: 10.1046/j.1365-2567.1996.472535.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goetzl E. J., Klickstein L. B., Watt K. W., Wintroub B. U. The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun. 1980 Dec 16;97(3):1097–1102. doi: 10.1016/0006-291x(80)91488-6. [DOI] [PubMed] [Google Scholar]
  12. Hwang D. R., Eckelman W. C., Mathias C. J., Petrillo E. W., Jr, Lloyd J., Welch M. J. Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography. J Nucl Med. 1991 Sep;32(9):1730–1737. [PubMed] [Google Scholar]
  13. Katayama S., Inaba M., Maruno Y., Omoto A., Itabashi A., Kawazu S., Ishii J. Effect of captopril or enalapril on renal prostaglandin E2. Prostaglandins. 1989 Oct;38(4):401–411. doi: 10.1016/0090-6980(89)90123-8. [DOI] [PubMed] [Google Scholar]
  14. Lechleitner P., Dzien A., Haring C., Glossmann H. Uneventful self poisoning with a very high dose of captopril. Toxicology. 1990 Dec 3;64(3):325–329. doi: 10.1016/0300-483x(90)90124-y. [DOI] [PubMed] [Google Scholar]
  15. Markham A., Goa K. L. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997 Aug;54(2):299–311. doi: 10.2165/00003495-199754020-00009. [DOI] [PubMed] [Google Scholar]
  16. Martin M. F., Surrall K. E., McKenna F., Dixon J. S., Bird H. A., Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984 Jun 16;1(8390):1325–1328. doi: 10.1016/s0140-6736(84)91821-x. [DOI] [PubMed] [Google Scholar]
  17. Miller L. C., Lynch E. A., Isa S., Logan J. W., Dinarello C. A., Steere A. C. Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet. 1993 Jan 16;341(8838):146–148. doi: 10.1016/0140-6736(93)90006-3. [DOI] [PubMed] [Google Scholar]
  18. Naftilan A. J., Pratt R. E., Dzau V. J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989 Apr;83(4):1419–1424. doi: 10.1172/JCI114032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Netea M. G., Hancu N., Blok W. L., Grigorescu-Sido P., Popa L., Popa V., van der Meer J. W. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine. 1997 Apr;9(4):284–287. doi: 10.1006/cyto.1996.0165. [DOI] [PubMed] [Google Scholar]
  20. Rezkalla S., Kloner R. A., Khatib G., Khatib R. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation. 1990 Mar;81(3):1039–1046. doi: 10.1161/01.cir.81.3.1039. [DOI] [PubMed] [Google Scholar]
  21. Schindler R., Dinarello C. A., Koch K. M. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine. 1995 Aug;7(6):526–533. doi: 10.1006/cyto.1995.0071. [DOI] [PubMed] [Google Scholar]
  22. Tarkowski A., Carlsten H., Herlitz H., Westberg G. Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease. Agents Actions. 1990 Aug;31(1-2):96–101. doi: 10.1007/BF02003227. [DOI] [PubMed] [Google Scholar]
  23. Tilg H., Dinarello C. A., Mier J. W. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today. 1997 Sep;18(9):428–432. doi: 10.1016/s0167-5699(97)01103-1. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES